middle.news
Can Cleo Diagnostics Revolutionize Early Ovarian Cancer Detection with CXCL10?
8:42am on Thursday 12th of June, 2025 AEST
•
Healthcare
Read Story
Can Cleo Diagnostics Revolutionize Early Ovarian Cancer Detection with CXCL10?
8:42am on Thursday 12th of June, 2025 AEST
Key Points
Patented CXCL10 biomarker enables early-stage ovarian cancer detection
Superior sensitivity and specificity compared to CA125 test
Staged market entry starting with U.S. pre-surgical diagnostics
Ongoing clinical trials and collaboration with University College London
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Cleo Diagnostics (ASX:COV)
OPEN ARTICLE